SEC Form 4 · accession 0001437749-26-020703
PUMA BIOTECHNOLOGY, INC. · PBYI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Allison Dorval
Director
Period of report
Jun 11, 2026
Accepted (ET)
Jun 15, 2026 · 8:09 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001401667
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 11, 2026 | A | 27,000 | $0.00 | A | 102,390 | D | |
| Common StockF3 | Jun 12, 2026 | S | 11,610 | $7.1989 | D | 90,780 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents Restricted Stock Units which vest in full on the earlier of the one-year anniversary of the date of grant and the date of the annual shareholder meeting following the date of grant, subject to the Reporting Person's continued service with the Issuer.
- F2Adoption date of referenced 10b5-1(c) plan is: 03-12-2025
- F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.98 to $7.32, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.